IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's earnings call reveals a steady financial performance with strong growth in technology and analytics solutions. Despite some uncertainties, the 'see more, win more' strategy and AI advancements are positive indicators. The Q&A section shows management's confidence in future growth and minimal P&L implications from strategic initiatives. The lack of specific guidance for 2026 is a minor concern, but overall, the positive growth trends and strategic developments suggest a positive stock price movement.
Key Financial Performance
Revenue for the third quarter $4.1 billion, grew 5.2% on a reported basis and 3.9% at constant currency. Excluding COVID-related work, revenue grew 4.5% at constant currency. This growth included about 1.5 points of contribution from acquisitions.
Technology & Analytics Solutions (TAS) revenue for the third quarter $1.631 billion, up 5% reported and 3.3% at constant currency.
R&D Solutions (R&DS) revenue for the third quarter $2.26 billion, growing 4.5% reported and 3.4% at constant currency. Excluding the step-down in COVID-related revenues, R&DS revenue grew 4.5% at constant currency.
Contract Sales & Medical Solutions (CSMS) revenue for the third quarter $209 million, up 16.1% reported and 13.9% at constant currency.
Adjusted EBITDA for the third quarter $949 million, representing growth of 1.1%.
Adjusted diluted EPS for the third quarter $3, increased 5.6% year-over-year.
Free cash flow for the third quarter $772 million, a record high, driven by disciplined working capital management and an improved industry backdrop.
Net bookings in the clinical side for the third quarter $2.6 billion, with a net book-to-bill ratio of 1.15x. Net bookings were 5% higher sequentially, 13% higher than a year ago, and 21% higher than Q1 2025, reflecting improving customer demand and solid sales execution.
Qualified pipeline Up 6% year-over-year, driven by large pharma and EBP segments.
RFP flow growth High single-digit sequential growth and 20% growth year-over-year, with growth across all segments.
Backlog at the end of the quarter $32.4 billion, showing growth of 4.1% compared to the prior year.
Year-to-date revenue $11.946 billion, up 4.4% reported and 3.7% at constant currency. Excluding all COVID-related work, year-to-date growth was approximately 4.5% at constant currency.
Year-to-date Technology & Analytics Solutions revenue $4.805 billion, up 6.7% reported and 5.8% at constant currency.
Year-to-date R&D Solutions revenue $6.563 billion, up 2.5% reported and 1.9% at constant currency. Excluding COVID-related work, revenue grew approximately 3.5% at constant currency.
Year-to-date CSMS revenue $578 million, up 6.8% reported and 5.9% at constant currency.
Third quarter GAAP net income $331 million, with GAAP diluted earnings per share of $1.93.
Year-to-date GAAP net income $846 million, or $4.86 of diluted earnings per share.
Adjusted net income for the third quarter $515 million, with adjusted diluted earnings per share of $3.
Year-to-date adjusted net income $1.48 billion, or $8.50 per share.
R&DS backlog at September 30 $32.4 billion, up 4.1% year-over-year. Next 12-month revenue from backlog was $8.1 billion, up 4.0% year-over-year.
Cash and cash equivalents as of September 30 $1.814 billion.
Gross debt as of September 30 $14.957 billion, resulting in net debt of $13.143 billion.
Net leverage ratio at the end of the quarter 3.52x trailing 12-month adjusted EBITDA.
Third quarter cash flow from operations $908 million.
Third quarter capital expenditures $136 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New drug launches: IQVIA supported multiple new drug launches, including oncology, metabolic therapy, and autoimmune disorder therapies. These launches utilized advanced AI capabilities for patient insights and performance tracking.
AI-enabled solutions: IQVIA is deploying approximately 90 specialized AI agents across 25 use cases in commercial, real-world, and R&D solutions. Clients are increasingly adopting AI-enabled platforms for global compliance reporting, omnichannel marketing, and analytics operations.
Commercial outsourcing: IQVIA observed a trend of large pharma clients outsourcing commercial operations for established brands in specific markets. This includes large multiyear engagements across therapies and geographies.
Global expansion: IQVIA secured a large award from a top 5 pharma client to manage end-to-end commercialization in a large overseas market.
Record free cash flow: Achieved the highest quarterly free cash flow ever at $772 million, driven by disciplined working capital management and an improved industry backdrop.
Revenue growth: Third quarter revenue grew 5.2% year-over-year to $4.1 billion, with strong contributions from Technology & Analytics Solutions and Contract Sales & Medical Solutions.
AI adoption: IQVIA is helping clients build robust, AI-ready data infrastructures, leveraging its healthcare-grade AI ecosystem.
CFO transition: Announced CFO transition with Mike Fedock succeeding Ron Bruehlman in February 2026, ensuring continuity in financial leadership.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Compliance: The company faces challenges in meeting regulatory commitments, as evidenced by the need for post-market studies and real-world evidence to fulfill regulatory requirements for newly approved drugs.
Economic Uncertainty: The company’s financial performance is influenced by foreign exchange rates and economic conditions, which could impact revenue growth and profitability.
Client Decision-Making Timelines: Although improving, delays in client decision-making timelines have been a challenge, potentially affecting the pace of project initiation and revenue realization.
COVID-Related Revenue Decline: The company experienced a step-down in COVID-related revenues, which has impacted year-over-year growth in certain segments.
Debt Levels: The company has a high level of gross debt ($14.957 billion) and a net leverage ratio of 3.52x, which could pose financial risks if not managed effectively.
Competitive Pressures: The company operates in a competitive environment, particularly in areas like AI-enabled solutions and commercial outsourcing, requiring continuous innovation and investment to maintain market position.
Supply Chain and Operational Risks: The company’s ability to execute large-scale, multi-year projects across geographies and therapies depends on robust operational capabilities, which could be disrupted by unforeseen challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2025 Revenue Guidance: Revenue is expected to be between $16.150 billion and $16.250 billion, representing year-over-year growth of 4.8% to 5.5% or 5.2% at the midpoint. This includes approximately $100 million of COVID-related revenue step down, 100 basis points of tailwind from foreign exchange, and 150 basis points of contribution from acquisitions.
Full Year 2025 Adjusted EBITDA Guidance: Expected to be between $3.775 billion and $3.8 billion, growing 2.5% to 3.1% year-over-year or 2.8% at the midpoint.
Full Year 2025 Adjusted Diluted EPS Guidance: Expected to be between $11.85 and $11.95, up 6.5% to 7.4% versus prior year or about 7% at the midpoint.
Fourth Quarter 2025 Revenue Guidance: Expected to be between $4.204 billion and $4.304 billion, representing year-over-year growth of 6.2% to 8.7%.
Fourth Quarter 2025 Adjusted EBITDA Guidance: Expected to be between $1.033 billion and $1.058 billion, representing growth of 3.7% to 6.2% versus prior year.
Fourth Quarter 2025 Adjusted Diluted EPS Guidance: Expected to be between $3.35 and $3.45, representing year-over-year growth of 7.4% to 10.6%.
R&D Solutions Backlog and Revenue Projections: R&DS backlog at September 30 was $32.4 billion, up 4.1% year-over-year. Next 12-month revenue from backlog is projected at $8.1 billion, up 4.0% year-over-year.
Clinical Demand Metrics: Forward-looking demand metrics in the clinical business show 20% RFP flow growth year-over-year and sequential improvement in client decision-making timelines.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How has the 'see more, win more' strategy contributed to RFP flows and win rates, and what are the P&L implications?
A:The 'see more, win more' strategy has contributed to growth by targeting previously untapped markets, reducing uncertainty in the market environment, and aligning pricing to market dynamics earlier in the year. The strategy has led to improved bookings momentum and RFP flow. The P&L implications are minimal, as only a small portion of the $32+ billion backlog was subject to earlier discounts, and the revenue impact will be negligible over the next five years.
Q:Is the momentum in TAS and R&DS expected to continue into 2026?
A:While specific 2026 guidance was not provided, the company expects to deliver over 5% top-line revenue growth this year, which is strong compared to peers. Management expressed confidence that 2026 revenue growth will be at least the same or better than this year.
Q:What are the differences between the pharma and biotech sides, and how are they performing?
A:Large pharma has completed reprioritization of programs, leading to normalized cancellation levels and strong RFP flow growth (20% year-over-year). Biotech funding is improving, driving EBP growth. Gross bookings and net bookings have been strong, with cancellations returning to regular patterns.
Q:What are the contributions of inorganic advancements to TAS, and what are the opportunities for expansion?
A:Inorganic advancements contributed 1.5 points to company growth, with 50-60% of that in TAS. Recent acquisitions include NEXT Oncology in R&DS and a CSMS deal. Opportunities for expansion include technology and analytics companies, AI innovations, and real-world evidence, which showed strong performance this quarter.
Q:What are the growth trends in TAS subcomponents like real-world evidence, consulting, and analytics?
A:Real-world evidence showed very strong growth, while consulting and analytics experienced low to mid-single-digit growth. Consulting, which had been negative earlier, is now positive and serves as a leading indicator of market improvement.
Q:What is the status of the two mega trials and the company's involvement in Phase I trials?
A:The two mega trials are not factored into Q4 guidance and are pushed out of the year. The company is expanding its presence in Phase I trials, particularly in oncology, as part of the 'see more, win more' strategy.
Q:How is AI impacting the company's operations and margins, and how are clients using AI?
A:The company is developing AI agents to improve efficiency and reduce labor, which will enhance margins over time. Clients use AI for drug discovery, marketing campaigns, and real-world patient insights. AI is also helping manage regulatory processes and site operations. Long-term, AI is expected to mitigate margin headwinds and improve profitability.
Q:What is the guidance for TAS in Q4 and the full year?
A:The company maintains its full-year guidance of 5-6% constant currency growth for TAS, with no changes from prior guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific 2026 guidance, citing the ongoing planning process and the usual practice of releasing guidance early in the year. Additionally, they did not provide detailed updates on the two mega trials due to confidentiality concerns, and their commentary on TAS Q4 guidance lacked specificity, leading to some ambiguity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Analytics Solutions
Bousbib
Bruehlman
CFO
CSMS
IQVIA Phase
IQVIA contract
IQVIA world
Phase II
Phase III
RD Solutions
Solutions currency
Solutions date
TAS
acquisition
agent
brand
cancer
capability pharma
capital
currency RD
date currency
date income
digit RFP
drug launch
engagement
finance
generation
indication
insight
momentum
oncology
portfolio
product
program AI
role
share date
strength
study commitment
therapy
transition
world study
IQV Transcript
IQVIA Holdings Inc. (IQV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
IQVIA Holdings Inc. (IQV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
IQVIA Holdings Inc. (IQV) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call reveals strong financial performance with revenue and EPS exceeding guidance, substantial share repurchases, and optimistic outlooks for demand in outsourced clinical development and Commercial Solutions. Despite some economic uncertainties, the constructive demand environment and increased AI-driven demand in Commercial Solutions are positive indicators. Share repurchases and solid cash flow further enhance shareholder value. The Q&A session confirms stable demand and growth drivers, with no significant negative trends highlighted. Overall, the sentiment is positive, likely resulting in a stock price increase of 2% to 8%.
IQVIA Holdings Inc. (IQV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
IQV Slides
IQV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
